Skip header and navigation

3 records – page 1 of 1.

Catechol-O-methyltransferase val108/158met genotype, major depressive disorder and response to selective serotonin reuptake inhibitors in major depressive disorder.

https://arctichealth.org/en/permalink/ahliterature146093
Source
Psychiatry Res. 2010 Mar 30;176(1):85-7
Publication Type
Article
Date
Mar-30-2010
Author
Ari Illi
Eija Setälä-Soikkeli
Olli Kampman
Merja Viikki
Timo Nuolivirta
Outi Poutanen
Heini Huhtala
Nina Mononen
Terho Lehtimäki
Esa Leinonen
Author Affiliation
University of Tampere, Medical School, Tampere, Finland. ari.illi@uta.fi
Source
Psychiatry Res. 2010 Mar 30;176(1):85-7
Date
Mar-30-2010
Language
English
Publication Type
Article
Keywords
Catechol O-Methyltransferase - genetics
Depressive Disorder, Major - drug therapy - genetics
Finland
Gene Frequency
Genome-Wide Association Study
Genotype
Humans
Methionine - genetics
Pharmacogenetics
Polymorphism, Single Nucleotide
Serotonin Uptake Inhibitors - therapeutic use
Valine - genetics
Abstract
The functional val108/158met polymorphism of the COMT gene (rs4680) was evaluated in major depressive disorder (MDD), and in the treatment response to antidepressants in MDD. We could not demonstrate any significant difference in the distribution of this COMT single-nucleotide polymorphism (SNP) in the treatment response to selective serotonin reuptake inhibitors or between patients with MDD and control subjects.
PubMed ID
20071037 View in PubMed
Less detail

Is 5-HTTLPR linked to the response of selective serotonin reuptake inhibitors in MDD?

https://arctichealth.org/en/permalink/ahliterature142078
Source
Eur Arch Psychiatry Clin Neurosci. 2011 Mar;261(2):95-102
Publication Type
Article
Date
Mar-2011
Author
Ari Illi
Outi Poutanen
Eija Setälä-Soikkeli
Olli Kampman
Merja Viikki
Heini Huhtala
Nina Mononen
Susann Haraldsson
Pasi A Koivisto
Esa Leinonen
Terho Lehtimäki
Author Affiliation
Medical School, University of Tampere, 33014 Tampere, Finland. ari.illi@uta.fi
Source
Eur Arch Psychiatry Clin Neurosci. 2011 Mar;261(2):95-102
Date
Mar-2011
Language
English
Publication Type
Article
Keywords
Adolescent
Adult
Aged
Chi-Square Distribution
Depressive Disorder, Major - drug therapy - genetics
Female
Finland
Genome-Wide Association Study
Genotype
Humans
Male
Middle Aged
Pharmacogenetics
Polymorphism, Genetic - genetics
Psychiatric Status Rating Scales
Serotonin Plasma Membrane Transport Proteins - genetics
Serotonin Uptake Inhibitors - therapeutic use
Young Adult
Abstract
The role of a functional polymorphism in the transcriptional control region of serotonin transporter gene (5-HTTLPR, SERTPR) has been studied intensively in major depression and in the response to selective serotonin inhibitors (SSRIs) in major depression. The findings have been contradictory, although majority of the studies indicate that the short allele is associated with poor response to SSRIs in major depression. In the present study, we evaluated the association of 5-HTTLPR with treatment response to SSRI medication in Finnish Caucasian MDD patients. A secondary purpose was to study the possible association of this particular polymorphism with major depressive disorder. The aim of the study was to replicate the previous findings in this area. Primary outcomes of the treatment were remission, defined by an exit score of seven or less, and response, defined by a reduction of at least 50% on the MADRS. We had also a control population of 375 healthy blood donors, as a secondary objective was to evaluate the possible association of this particular polymorphism with major depressive disorder. Twenty-nine of the 85 (34.1%) patients reached the remission and 58.8% achieved the predefined response criteria. The l/l genotype of 5-HTTLPR was presented in 51.7% of those patients who achieved remission vs. 25.0% in the non-remitters (P = 0.03). The result remained statistically significant after adjusting for age, gender, medication and MADRS points at the study entry. However, the small sample size limits the reliability of this result.
PubMed ID
20640435 View in PubMed
Less detail

No support for a role for BDNF gene polymorphisms rs11030101 and rs61888800 in major depressive disorder or antidepressant response in patients of Finnish origin.

https://arctichealth.org/en/permalink/ahliterature117953
Source
Psychiatr Genet. 2013 Feb;23(1):33-5
Publication Type
Article
Date
Feb-2013
Author
Ari Illi
Merja Viikki
Outi Poutanen
Eija Setälä-Soikkeli
Timo Nuolivirta
Olli Kampman
Esa Leinonen
Heini Huhtala
Nina Mononen
Terho Lehtimäki
Author Affiliation
Medical School, University of Tampere, Tampere, Finland.
Source
Psychiatr Genet. 2013 Feb;23(1):33-5
Date
Feb-2013
Language
English
Publication Type
Article
Keywords
Adult
Antidepressive Agents - therapeutic use
Brain-Derived Neurotrophic Factor - genetics
Case-Control Studies
Demography
Depressive Disorder, Major - drug therapy - genetics
Female
Finland
Genetic Predisposition to Disease
Humans
Male
Polymorphism, Single Nucleotide - genetics
Abstract
Brain-derived neurotrophic factor (BDNF) is suggested to play a role in the aetiology of major depression and in the antidepressant response in patients with major depression. Several BDNF gene polymorphisms have been investigated in the above-mentioned context. The aim of the present study was to examine the role of two BDNF gene polymorphisms (rs11030101 and rs61888800) in relation to the response to selective serotonin reuptake inhibitor medication in 106 patients of Finnish origin suffering from major depression. The secondary objective was to evaluate the association of these two BDNF polymorphisms in major depression, as we also had a control population of 386 healthy individuals. We did not find any significant differences in the distribution of these two BDNF gene polymorphisms in our patient population in relation to remission or response to treatment with selective serotonin reuptake inhibitor. Also, there were no significant differences between the patients and the controls.
PubMed ID
23250003 View in PubMed
Less detail